Relevant bibliographies by topics / Analogues de nucléos(t)ides

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers
  5. Reports

Academic literature on the topic 'Analogues de nucléos(t)ides'

Author: Grafiati
Published: 4 June 2021
Last updated: 12 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Analogues de nucléos(t)ides.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Analogues de nucléos(t)ides"

1

Sombié, R., L. Sangaré, A. Guingané, A. Tiendrébéogo, D. Kaboré, and A. Bougouma. "Traitement de l’hépatite B chronique par les analogues de nucléos(t)ides." Journal Africain d'Hépato-Gastroentérologie 9, no. 3 (2015): 114–18. http://dx.doi.org/10.1007/s12157-015-0601-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Chang, Ruei-Hsin, Tsolmon Nyamsuren, Sarvesh Gyawali, Yi-Wen Huang, Rui-Ting Hu, and Sien-Sing Yang. "Long-Term Nucleos(T) Ides Analogues Improve Liver and Spleen Size." Ultrasound in Medicine & Biology 43 (2017): S168. http://dx.doi.org/10.1016/j.ultrasmedbio.2017.08.1558.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Roade, Luisa, Mar Riveiro-Barciela, Rafael Esteban, and Maria Buti. "Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B." Therapeutic Advances in Infectious Disease 8 (January 2021): 204993612098595. http://dx.doi.org/10.1177/2049936120985954.

Full text
Abstract:
Nucleos(t)ide analogues with high barrier to resistance are regarded as the principal therapeutic option for chronic hepatitis B (CHB). Treatment with entecavir (ETV), tenofovir disoproxil (TDF) and the later released tenofovir alafenamide (TAF) is highly effective at controlling hepatitis B virus (HBV) infection and, in the vast majority of patients, is well tolerated. No significant differences in viral suppression have been described among the different regimens, although an earlier achievement in biochemical response has been suggested first under TDF and recently under TAF. High barrier to resistance NAs rarely achieve hepatitis B surface antigen sero-clearance, and therefore should be maintained life-long in most cases. This has increased concerns about treatment-related toxicity, especially in patients under TDF with additional risk factors for kidney and bone impairment. TAF has shown a better bone and kidney safety profile than TDF, although it is not yet available worldwide due to its higher cost. Emergence of adverse events should be monitored since treatment-switch to ETV/TAF seems to be effective and safe in HBV mono-infected subjects. Finally, although an effective antiviral treatment leads to a clear improvement in clinical outcome of CHB patients; the risk of developing hepatocellular carcinoma (HCC) is not completely avoided with viral suppression. Whether tenofovir-based regimens provide any additional benefit over ETV in HCC prevention remains unclear and requires further investigation.
APA, Harvard, Vancouver, ISO, and other styles
4

Jang, Tyng‐Yuan, Yu‐Ju Wei, Cheng‐Ting Hsu, et al. "Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos(t)ides analogues therapy." Journal of Gastroenterology and Hepatology 35, no. 11 (2020): 1886–92. http://dx.doi.org/10.1111/jgh.15061.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Chang, Ruei-Hsin, Tsolmon Nyamsuren, Sarvesh Gyawali, et al. "Long-term Nucleos(t)ides Analogues for Chronic Hepatitis B Improve Liver and Spleen Size: A Noninvasive Sonographic Study." Journal of Medical Ultrasound 25, no. 3 (2017): 161–66. http://dx.doi.org/10.1016/j.jmu.2017.03.013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Viganò, M., P. Lampertico, C. Eller-Vainicher, et al. "F-33 High prevalence of reduced bone mineral density in patients with chronic hepatitis B under nucleos(t)ides analogues treatment." Digestive and Liver Disease 43 (February 2011): S102. http://dx.doi.org/10.1016/s1590-8658(11)60118-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Striki, Athanasia, Spilios Manolakopoulos, Melanie Deutsch, et al. "Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B." Liver International 37, no. 11 (2017): 1642–50. http://dx.doi.org/10.1111/liv.13432.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

ISLAM, M. M., R. J. LUDDY, and A. V. PROKUDIN. "NEAR FORWARD pp ELASTIC SCATTERING AT LHC AND NUCLEON STRUCTURE." International Journal of Modern Physics A 21, no. 01 (2006): 1–41. http://dx.doi.org/10.1142/s0217751x06028473.

Full text
Abstract:
High energy pp and [Formula: see text] elastic scattering carried out at CERN ISR and SPS Collider and at Fermilab Tevatron are studied first in a model where the nucleon has an outer cloud and an inner core. Elastic scattering is viewed as primarily due to two processes: (a) diffraction scattering originating from cloud–cloud interaction; (b) a hard or large |t| scattering originating from one nucleon core scattering off the other via vector meson ω exchange, while their outer clouds interact independently. For small |t| diffraction dominates, but the hard scattering takes over as |t| increases. The ω-exchange amplitude shows that ω behaves like an elementary vector meson at high energy, contrary to a regge pole behavior. This behavior, however, can be understood in the nonlinear σ-model where ω couples to a topological baryonic current like a gauge boson, and the nucleon is described as a topological soliton. Further investigation shows that the underlying effective field theory model is a gauged Gell-Mann–Levy type linear σ-model that has not only the pion sector and the Wess–Zumino–Witten action of the nonlinear σ-model, but also a quark sector where quarks and antiquarks interact via a scalar field. The scalar field vanishes near the center of the nucleon, but rises sharply at some critical distance to its vacuum value fπ leading to a [Formula: see text] condensate analogous to a BCS condensate in superconductivity. The nucleon structure that emerges then is that the nucleon has an outer cloud of [Formula: see text] condensed ground state, an inner core of topological baryonic charge probed by ω, and a still smaller quark-bag containing massless valence quarks. Large |t|pp elastic scattering is attributed to valence quark–quark elastic scattering, which is taken to be due to the hard pomeron (BFKL pomeron with next to leading order corrections). The parameters in the model are determined by requiring that they satisfactorily describe the known asymptotic behavior of σ tot (s) and ρ(s), and the measured [Formula: see text] at [Formula: see text], 630 GeV, and 1.8 TeV. The model is then used to predict pp elastic differential cross-section at LHC at [Formula: see text] and |t| = 0–10 GeV 2. Our predicted dσ/dt at 14 TeV is found to be very different from those predicted by the impact-picture model and the eikonalized pomeron–reggeon model. Precise measurement of dσ/dt at LHC by the TOTEM group will be able to distinguish between these models. If our predicted dσ/dt is quantitatively confirmed, then it will indicate that various novel ideas developed to describe the nucleon combine and lead to a unique physical description of its structure.
APA, Harvard, Vancouver, ISO, and other styles
9

Canzoni, Marco, Massimo Marignani, Maria Laura Sorgi, et al. "Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy." Microorganisms 8, no. 11 (2020): 1792. http://dx.doi.org/10.3390/microorganisms8111792.

Full text
Abstract:
Chronic hepatitis B virus (HBV) infection may be reactivated by immunosuppressive drugs in patients with autoimmune inflammatory rheumatic diseases. This study evaluates HBV serum markers’ prevalence in rheumatic outpatients belonging to Spondyloarthritis, Chronic Arthritis and Connective Tissue Disease diagnostic groups in Italy. The study enrolled 302 subjects, sex ratio (M/F) 0.6, mean age ± standard deviation 57 ± 15 years, 167 (55%) of whom were candidates for immunosuppressive therapy. The Spondyloarthritis group included 146 subjects, Chronic Arthritis 75 and Connective Tissue Disease 83 (two patients had two rheumatic diseases; thus, the sum is 304 instead of 302). Ten subjects (3%) reported previous anti-HBV vaccination and tested positive for anti-HBs alone with a titer still protective (>10 IU/mL). Among the remaining 292 subjects, the prevalence of positivity for HBsAg, isolated anti-HBc, anti-HBc/anti-HBs, and any HBV marker was 2%, 4%, 18%, and 24%, respectively. A total of 26/302 (9%) patients with γ-globulin levels ≤0.7 g/dL were more frequently (p = 0.03455) prescribed immunosuppressive therapy, suggesting a more severe rheumatic disease. A not negligible percentage of rheumatic patients in Italy are at potential risk of HBV reactivation related to immunosuppressive therapy. Before starting treatment, subjects should be tested for HBV markers. Those resulting positive should receive treatment or prophylaxis with Nucleos (t) ides analogue (NUCs) at high barrier of resistance, or pre-emptive therapy, according to the pattern of positive markers. HB vaccination is recommended for those who were never exposed to the virus.
APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Analogues de nucléos(t)ides"

1

Lucifora, Julie. "Etude de la réplication du VHB et de la réponse à l'intracellulaire à l'infection virale." Phd thesis, Université Claude Bernard - Lyon I, 2008. http://tel.archives-ouvertes.fr/tel-00342583.

Full text
Abstract:
Le VHB est un problème majeur puisque les 350 millions de porteurs chroniques existant ont un risque accru de développer une cirrhose ou un carcinome hépatocellulaire. Compte tenu du manque de système d'étude du VHB in vitro qui soit facile d'accès et pleinement satisfaisant, l'objectif était d'améliorer l'un de ceux qui utilisent des baculovirus VHB recombinants pour délivrer le génome VHB dans des cellules hépatocytaires. La pertinence de ce système pour réaliser des tests phénotypiques et étudier le « fitness » des mutants résistants aux antiviraux a ensuite été démontrée. Enfin, l'utilisation de ces baculovirus VHB recombinants dans des cellules HepaRG a permis de mettre en évidence une réponse IFN efficace de l'hépatocyte suite à la synthèse des protéines du VHB. Ceci constitue une donnée nouvelle dans l'étude des interactions virus/cellules puisque le VHB était considéré jusqu'à présent comme un virus silencieux vis-à-vis de la réponse innée cellulaire. L'ensemble de ces résultats a des implications importantes dans la compréhension des mécanismes de persistance du VHB et le développement de nouveaux modèles cellulaires d'infection.
APA, Harvard, Vancouver, ISO, and other styles
2

Velay, Aurélie. "Influence des protéines d’enveloppe du virus de l’hépatite B sur la disparition de l’antigène HBs circulant lors du traitement de l’hépatite chronique B par analogues nucléos(t)idiques : mécanismes moléculaires impliqués et développement d’un traitement immunomodulateur à base d’anticorps monoclonaux." Thesis, Université de Lorraine, 2015. http://www.theses.fr/2015LORR0284/document.

Full text
Abstract:
L'hépatite B chronique reste un problème majeur de santé publique. Sous traitement par analogues nucléos(t)idiques (NUCs), l'objectif thérapeutique ultime est la clairance de l'antigène (Ag) HBs. Nous avons étudié l'influence de la variabilité des protéines d'enveloppe, impliquées dans l'entrée cellulaire du virus et cibles de la réponse immune, sur la clairance de l'Ag HBs. Des patients traités par NUCs ayant obtenu une clairance de l'Ag HBs (resolvers) ont été appariés à des non-resolver. Deux mutations combinées sT125M/sP127T, caractéristiques des non-resolver, étaient associées à une baisse de l'antigénicité prédite. L'analyse par séquençage haut débit montrait une plus grande variabilité du gène S chez les non resolver. Des tests fonctionnels portant sur des particules virales mutées en sT125M et sP127T sont en cours. Ces données moléculaires sont en faveur de l'existence de "motifs" spécifiques dans le gène S associés à la persistance de l'Ag HBs sous traitement par NUCs<br>Hepatitis B virus (HBV)-related chronic infection remains difficult to eradicate. On treatment by nucleos(t)ide analogues (NUCs), HBs Antigen (Ag) clearance is the ultimate but difficult therapeutic goal. Our aim was to investigate how variability of HBV envelope protein, crucial in viral cellular entry and targeted by host immune response, could play a role in HBsAg clearance. HBV chronically infected patients, treated by NUCs with HBsAg clearance (resolver) were matched with patients without HBsAg clearance (non resolver). Combined mutations sT125M/sP127T, associated with HBsAg persistence, displayed a lower predicted antigenicity. Ultra Deep Sequencing of S gene showed a higher variability in non resolver. Functional assays on viral particles including sT125M and sP127T mutations versus reference particles are in progress. As a conclusion, molecular features observed in non NR argue in favor of a different pattern in HBV S characteristics according to variable NUCs efficiency
APA, Harvard, Vancouver, ISO, and other styles
3

Riveiro, Barciela María del Mar. "Estudio de dos situaciones especiales en pacientes con infección crónica por el virus de la hepatitis B: Eficacia y seguridad de los análogos de nucleós(t)idos de segunda generación en una cohorte de práctica clínica real y nuevos biomarcadores para la identificación de portadores inactivos." Doctoral thesis, Universitat Autònoma de Barcelona, 2016. http://hdl.handle.net/10803/399831.

Full text
Abstract:
La hepatitis B es un problema de salud mundial, con unos 400 millones de personas infectadas crónicamente. En nuestro medio se calcula una prevalencia del 0.7%, siendo la mayoría de los sujetos HBeAg negativo. En esta fase de la infección, uno de los retos es distinguir entre aquellos sujetos portadores inactivos, que presentarán un buen pronóstico de la enfermedad a largo plazo, y los pacientes con hepatitis crónica HBeAg negativo, que tienen riesgo de desarrollar fibrosis hepática y por tanto precisar tratamiento antiviral. El primer trabajo se centró en pacientes bajo tratamiento antiviral con análogos de nucleós(t)idos de segunda generación (Entecavir y Tenofovir). Las hipótesis del mismo fueron que la eficacia y tasa de efectos adversos en práctica clínica era similar a la de los estudios de registro y la validación del modelo Page-B para predicción del riesgo de carcinoma hepatocelular (CHC). Para dicho fin se analizó la base CIBERHEP que incluye sujetos con infección crónica por el VHB, seleccionándose un total de 609 pacientes caucásicos en tratamiento con Tenofovir o Entecavir. Las tasas de respuesta virológica y bioquímica fueron altas, con pocos efectos adversos y discontinuación de tratamiento, sin observarse deterioro de la función renal. A pesar de la supresión de la replicación viral, se observaron 12 casos de CHC, número inferior a los estimados por la puntuación Page-B. Al igual que en la cohorte original, todos aquellos sujetos que presentaron CHC tenían basalmente una puntuación Page-B ≥10 puntos, confirmándose el valor predictivo negativo del 100% de dicho punto de corte. La hipótesis del segundo de los estudios, fue que los niveles séricos de antígeno de superficie (HBsAg) o antígeno relacionado con el core (HBcrAg) podrían ser útiles para identificar a los verdaderos portadores inactivos del VHB. Para ello se realizó un estudio prospectivo con al 3 determinaciones analíticas en 1 año para caracterizar a los sujetos como portadores inactivos (niveles de alanino transferasa persistentemente normales y ADN VHB≤2.000 UI/mL) o con actividad por el VHB. En primer lugar se observó que los niveles de HBsAg estaban influidos el por genotipo del VHB, dato que dificultó la búsqueda de un único punto de corte con altos índices diagnósticos en todos los genotipos, siendo el HBsAg <3 logUI/mL útil sólo para el genotipo D. Por contra, los niveles de HBcrAg no difirieron entre los diferentes genotipos, siendo la exactitud diagnóstica para la identificación de portadores inactivos mayor que los niveles de HBsAg. La combinación en una única determinación de HBcrAg ≤3 logU/mL más ADN VHB ≤2.000 UI/mL presentó una exactitud diagnóstica >85% en todos los genotipos excepto el H o F (73%).<br>Hepatitis B virus (HBV) infection is a worldwide health problem, with around 400 million people chronically infected. In our setting, the prevalence is 0.7% and the majority of subjects are HBeAg negative. In this stage of the disease, one of the most challenging issues is to discern between the inactive carriers, who have a long-term good prognosis of the disease, and patients with HBeAg negative chronic hepatitis B, who are at risk of fibrosis development and therefore may require antiviral therapy. The first study of this thesis is focus on patients undergoing antiviral therapy with second generation nucleos(t)tides analogs (Entecavir and Tenofovir). The hypotheses were that the effectiveness and rate of side effects in daily clinical practice were similar to the registration studies and the validation of the Page-B score for prediction of hepatocellular carcinoma (HCC) development. From the collaborative database CIBERHEP, 609 caucasian subjects with chronic hepatitis B treated with Tenofovir or Entecavir were selected. The rates of biochemical and virological response were very high, and no worsening on renal function was observed. Despite suppression of viral replication, 12 cases of HCC were reported, a number lower to the estimated by the Page-B score. Similar to the original cohort, in the CIBERHEP all patients who developed HCC presented a baseline Page-B punctuation ≥10 points, supporting the previously described 100% negative predictive value of that cut-off. The hypothesis of the second study was that the serum levels of hepatitis B antigen (HBsAg) o core-related antigen (HBcrAg) could be useful for identification of HBV inactive carriers. To achieve this goal, a prospective work with 3 consecutive blood analyses throughout 1 year was carried out. Subjects were classified as inactive carriers (defined as persistently normal alanine transferase levels and HBV DNA ≤2.000 IU/mL) or subjects with HBV activity. Firstly, it was observed that HBsAg levels varied across the different HBV genotypes. This finding hindered the search of a unique HBsAg cut-off for diagnosing the inactive carrier state among the different HBV genotypes. Previously described HBsAg <3 logIU/mL was only useful of genotype D. However, HBcrAg did no vary among genotypes, and on the whole, the diagnostic accuracy of HBcrAg was higher than HBsAg levels. The combination on a single determination of HBcrAg ≤3 logU/mL plus HBV DNA ≤2.000 IU/mL presented a diagnostic accuracy ≥85% in all genotypes except H or F (73%).
APA, Harvard, Vancouver, ISO, and other styles
4

Santos, Maria Isabel Magalhães Andrade dos. "Perfil das mutações de resistência do vírus da Hepatite B aos análogos de nucleos(t)ídeos entre pacientes com hepatite B crônica." Centro de Pesquisas Gonçalo Moniz, 2014. https://www.arca.fiocruz.br/handle/icict/8687.

Full text
Abstract:
Submitted by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2014-10-29T13:42:36Z No. of bitstreams: 1 Maria Isabel Magalhães Santos Perfil das....pdf: 1133942 bytes, checksum: bcc264f7cc24ec022846c05825fd31cf (MD5)<br>Made available in DSpace on 2014-10-29T13:42:36Z (GMT). No. of bitstreams: 1 Maria Isabel Magalhães Santos Perfil das....pdf: 1133942 bytes, checksum: bcc264f7cc24ec022846c05825fd31cf (MD5) Previous issue date: 2014<br>Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil<br>Introdução: A doença causada pelo vírus da hepatite B (HBV) é um problema de saúde pública mundial. No Brasil, o sistema único de saúde (SUS) tem disponibilizado drogas antivirais para o tratamento de hepatite B crônica há mais de 10 anos, mas um sistema para o monitoramento e avaliação de resistência a estas drogas ainda não está disponível. Objetivo: Este estudo teve como objetivo determinar o perfil de mutações do HBV associadas com a resistência aos análogos de nucleos(t)ídeos entre 81 pacientes com infecção crônica pelo HBV: virgens de tratamento para hepatite B e tratados com diferentes análogos de nucleosídeos e nucleotídeos, no Hospital Professor Edgar Santos (HUPES-UFBA)- Salvador-BA. Metodologia: O HBV-DNA foi isolado de amostras de soro, amplificado por nested-PCR, utilizando-se primers deduzidos da região flaqueadora da domínio rt do gene P e sequenciados (ABI Prism 3730, Applied Biosystems, EUA). Duas a seis sequências de cada isolado foram alinhados e os sítios conflitantes foram resolvidos usando o software CLC Main Workbench v. 5.0 por inspeção visual dos eletroferogramas. As sequências consenso tinham um tamanho de 1032 pb (compreendendo os aminoácido 1-344 da rt). Estas sequências foram submetidas ao banco de dados HBVrt DB (Stanford University, EUA) para a análise de cada mutação de acordo com o genótipo e tratamento. Resultado: O genótipo A1 foi o mais prevalente (85,2%) seguido pelo genótipo A2 (4,9%) F (6,2%) e C1, D2 e D4 (1,2% cada). Seis pacientes (7 %) apresentaram mutações de resistência para LAM, ETV, TDF: dois com o padrão L180M + M204V e quatro com padrões diversos (L80I + L180M + M204I ;L80V + L180M + M204V; M204I; A194T). Todas estas mutações foram associadas ao genótipo A (quatro A1 e dois A2). Além disso, foi encontrado um paciente com HBV genótipo C típico do leste da Ásia. Destes pacientes, dois foram virgens de tratamento e quatro tinham histórico de tratamento para HIV ou HBV. Foram detectadas quatro mutações no gene S (três casos com a mutação sI195M e um a mutação sW196L) associadas às mutações do domínio rt do gene P, correspondendo à uma taxa de 6% de mutações de escape vacinal. A prevalência das mutações de resistência às drogas antivirais variou de acordo com a duração do tratamento e com o nível da barreira genética da droga utilizada. Neste estudo, foi encontrada uma forte associação entre a ocorrência de mutações de resistência do HBV e positividade para o AgHBe, co-infecção com o HIV e histórico de tratamento para HBV e/ou HIV. Conclusão: Antes da terapia ser iniciada é extremamente importante o monitoramento da carga viral e a identificação destas mutações para suportar decisões clinicas sobre o manejo dos pacientes e prevenir a emergência de vírus multi- resistentes.<br>Introduction: Hepatitis B virus (HBV) infection is a public health issue. The Brazilian public health system (SUS) has provided antiviral drugs for chronic hepatitis B treatment for over 10 years, but a system for monitoring for drug-related resistance mutations is not available. Objective: This study aims to determine the presence of HBV mutations associated with resistance to nucleos(t)ide analogs among 81 patients with chronic HBV infection-naïve and treated from University Hospital Professor Edgard Santos, Salvador-BA (HUPES-UFBA). Methods: Briefly, HBV-DNA was PCR amplified with primers deduced from the flanking of the rt domain at the HBV P gene and sequenced using ABI Prism 3730 (Applied Biosystems, USA). From two to six forward and reverse sequences of each isolate were assembled and conflicting sites were resolved using software CLC Main Workbench v. 5.0 by visual inspection of the electropherograms. Consensus sequence extended 1032 bp and encompassed the entire rt domain (from amino acid 1 to 344). Those sequences were submitted to the HBV drug resistance database (HBVrt DB, Stanford University, USA) to retrieve each mutation according to genotype and treatment. Results: HBV genotype A1 (85.2%) was the most prevalent followed by genotype A2 (4.9%), F (6.2%), and C1, D2 and D4 (1.2% each). Six patients (7%) exhibited resistance mutations to LAM, ETV and TDF: two with patterns L180M + M204V and four with other different patterns: L80I + L180M + M204I; L80V + L180M + M204V; M204I; A194T. All of these mutations were present in patients with genotype A (four A1 and two A2). Furthermore, this study found one patient with genotype C, common in East Asian. Of these patients, two were naïve and four had a history of treatment for HIV or HBV. In addition, four mutations in gene S (sI195M three cases with the mutation and one with the mutations W196L) associated with mutations in the rt domain of the P gene were detected, corresponding to a rate of 6% of vaccine escape mutations. Prevalence of drug-related resistance mutations varied according to treatment duration and the level of genetic barrier for the drugs used. Conclusion: In this study a strong association was found between the occurrence of HBV resistance mutations and HBeAg positivity, co-infection with HIV and a history of treatment for HBV and / or HIV. Once the drug therapy is initiated it is extremely important to monitor viral load and identify those mutations in order to support clinical decisions about patient management and also to prevent the emergence of multidrug-resistant viruses.
APA, Harvard, Vancouver, ISO, and other styles
5

Nishijima, Norihiro. "Dynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencing." Kyoto University, 2013. http://hdl.handle.net/2433/174771.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Chen, Kwei-Ming, and 陳奎閔. "Efficacy and Safety of Tenofovir for Chronic Hepatitis B Patients After Suboptimal Virological Response to Other Nucleos(t)ide Analogues Treatment." Thesis, 2016. http://ndltd.ncl.edu.tw/handle/uy92rp.

Full text
Abstract:
碩士<br>中山醫學大學<br>醫學研究所<br>104<br>Introductions: A suboptimal response is common in chronic hepatitis B (CHB) patients treated with Lamivudine (LAM), Adefovir (ADV), Telbivudine (LdT) or Entecavir (ETV); either by monotherapy or combination therapy. This study is aimed to evaluate the efficacy and safety of Tenofovir (TDF) monotherapy for CHB patients after suboptimal virological response (SOR) to other nucleos(t)ide analogues (NUC) treatment. Methods: From September 2011 to December 2015, we retrospectively analyzed CHB patients with SOR to other NUCs treatment. Patients subsequently received TDF monotherapy at least 24 weeks were included. Hepatitis B virus (HBV) DNA, HbsAg and other biochemistries were monitored every 3-6 months. The primary endpoint was defined as an undetectable HBV DNA level during TDF treatment. Secondary endpoints were hepatitis B envelop antigen (HBeAg) seroclearance and safety of renal function. Results: A total of 22 patients were included in the study. Twelve (54.5 %) patients achieved CVR after median 127 weeks treatment. Seven patients (31.8%) achieved CVR early at 24 weeks of TDF treatment. Patients did not achieved CVR also had marked HBV DNA suppression after TDF treatment. Three of fourteen patients (21.4%) developed HbeAg seroclearance. No patient developed renal impairment during TDF treatment. The prior Nucs treatment duration had impact on CVR rate (p = 0.048). Conclusions: TDF monotherapy is a potent rescue therapy for CHB patients with SOR to other Nucs. Longer prior Nucs treatment had marginal effect on CVR rate. Patient’s renal function remained stable after TDF treatment, even in those with baseline eGFR< 80 ml/min 1.73 m2.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Analogues de nucléos(t)ides"

1

Viganò, Mauro, Massimo Puoti, and Pietro Lampertico. "Nucleos(t)ide Analogue Based Therapy and Management of Patients." In Molecular and Translational Medicine. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-22330-8_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

"Can we Stop Nucleos(t)ide Analogs in HBV Chronic Hepatitis?" In What is New in Gastroenterology and Hepatology, edited by Roxana Șirli. BENTHAM SCIENCE PUBLISHERS, 2021. http://dx.doi.org/10.2174/9781681087870121010027.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Chevaliez, Stéphane, and Jean-Michel Pawlotsky. "15. Prévention, diagnostic et prise en charge de la résistance aux analogues nucléos(t)idiques dans l’hépatite chronique B." In Hépatite B. EDP Sciences, 2020. http://dx.doi.org/10.1051/978-2-84254-223-8-018.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Chevaliez, Stéphane, and Jean-Michel Pawlotsky. "15. Prévention, diagnostic et prise en charge de la résistance aux analogues nucléos(t)idiques dans l’hépatite chronique B." In Hépatite B. EDP Sciences, 2020. http://dx.doi.org/10.1051/978-2-84254-223-8.c018.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Irving, Will. "Case 44." In Oxford Case Histories in Infectious Diseases and Microbiology, edited by Bridget Atkins. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198846482.003.0044.

Full text
Abstract:
Healthcare workers can transmit blood-borne virus (BBV) infections to their patients during the course of performing exposure prone procedures. To reduce the risk of this happening, healthcare workers entering the National Health Service who wish to perform EPPs in the UK must be tested for BBV infection. Hepatitis B- infected healthcare workers may perform EPPs providing they are HBE antigen negative and have a viral load below 200 IU/ml, subject to annual viral load checks. If their viral load is &gt;200 but &lt; 20,000 IU/ml, then they may suppress HBV replication using nucleos(t)ide analogue antiviral therapy, subject to 3-monthly viral load measurement. Healthcare workers known to be currently infected with hepatitis C virus are not allowed to perform EPPs but may do so if they are clear of HCV RNA 12 weeks after antiviral therapy. HIV-infected healthcare workers may perform EPPs if their viral load is suppressed to &lt; 200 copies/ml whilst on combination antiretroviral therapy, subject to 3-monthly monitoring.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Analogues de nucléos(t)ides"

1

van Bömmel, F., K. Stein, R. Heyne, et al. "Response to discontinuation of nucleos(t)ide analogue treatment in HBeAg-negative chronic hepatitis B: results from the Stop-NUC trial." In DGVS Digital: BEST OF DGVS. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1716038.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yen, Chieh-Ling, Wei-Wen Su, Chih-Sheng Wu, et al. "IDDF2018-ABS-0154 Virological and clinical outcomes after cessation of nucleos(t)ide analogue therapy for chronic hepatitis b – a prospective cohort study in central taiwan." In International Digestive Disease Forum (IDDF) 2018, Hong Kong, 9–10 June 2018. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2018. http://dx.doi.org/10.1136/gutjnl-2018-iddfabstracts.223.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Yip, Terry Cheuk-Fung, Grace Lai-Hung Wong, Yee-Kit Tse, Henry Lik-Yuen Chan, and Vincent Wai-Sun Wong. "IDDF2018-ABS-0058 Early normalisation of alanine aminotransferase (alt) after nucleos(t)ide analogue treatment reduces the risk of hepatocellular carcinoma (hcc) in patients with chronic hepatitis b – a territory-wide study of 21,182 subjects." In International Digestive Disease Forum (IDDF) 2018, Best Abstracts, Hong Kong, 9–10 June 2018. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2018. http://dx.doi.org/10.1136/gutjnl-2018-iddfbestabstracts.16.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Analogues de nucléos(t)ides"

1

Chen, Mao-bing, Hua Wang, Qi-han Zheng, Wei-yan Cui, Hua-lan Xu, and Xu-wen Zheng. Comparative efficacy of the front-line anti-HBV drugs in nucleos(t)ide analogue-naive chronic hepatitis B, A protocol for systematic review and network meta-analysis. INPLASY - International Platform of Registered Systematic Review Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.3.0016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography